NCT00947856

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

Study Contact:

Study Phase:

PHASE2

Recruitment Status:

COMPLETED

NCT ID:

NCT00947856

Principal Investigator:

Study Type:

INTERVENTIONAL

Official Title:

Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study

Summary

This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.

Eligibility

Inclusion Criteria:

* Participated in a previous brentuximab vedotin study.
* CD30-positive hematologic malignancy.
* At a minimum, experienced clinical benefit in the prior brentuximab vedotin study. For retreatment, patients must have previously achieved either complete or partial remission with brentuximab vedotin and experienced disease progression after discontinuing the prior brentuximab vedotin study.

Exclusion Criteria:

Withdrew consent to participate in any prior brentuximab vedotin study.

Disease(s) and\or Condition(s)

Disease, Hodgkin

Lymphoma, Large-Cell, Anaplastic

Lymphoma, Non-Hodgkin

Primary Purpose

TREATMENT

Intervention/Treatment

- Type: DRUG
- Name: brentuximab vedotin
- Description: Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure
- Arm Group Labels: BV Extension, BV Retreatment

Sponsor

Seagen Inc.